Nykredit A/S’s Supernus Pharmaceuticals SUPN Stock Holding History

Nykredit A/S’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110K	Buy	+2,367	New	+$114K	﹤0.01%	1283

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nykredit A/S's SUPN Position: Q2 2026 in Review

Nykredit A/S opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 2,367 shares worth $110K. The stake represents ﹤0.01% of the portfolio and ranks #1283 among its holdings.

242 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Nykredit A/S held 2,367 shares of Supernus Pharmaceuticals worth $110K as of Q2 2026.
Supernus Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1283 holding.
242 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.